- Home
- POR vs CYTK Comparison
POR vs CYTK Comparison
Compare POR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- CYTK
- Stock Information
- Founded
- POR 1889
- CYTK 1997
- Country
- POR United States
- CYTK United States
- Employees
- POR N/A
- CYTK N/A
- Industry
- POR Electric Utilities: Central
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- POR Utilities
- CYTK Health Care
- Exchange
- POR Nasdaq
- CYTK Nasdaq
- Market Cap
- POR 4.9B
- CYTK 5.6B
- IPO Year
- POR N/A
- CYTK 2004
- Fundamental
- Price
- POR $42.44
- CYTK $31.70
- Analyst Decision
- POR Hold
- CYTK Buy
- Analyst Count
- POR 11
- CYTK 19
- Target Price
- POR $45.78
- CYTK $77.33
- AVG Volume (30 Days)
- POR 965.0K
- CYTK 2.3M
- Earning Date
- POR 04-25-2025
- CYTK 05-06-2025
- Dividend Yield
- POR 4.95%
- CYTK N/A
- EPS Growth
- POR 8.87
- CYTK N/A
- EPS
- POR 2.86
- CYTK N/A
- Revenue
- POR $3,439,000,000.00
- CYTK $19,218,000.00
- Revenue This Year
- POR $4.88
- CYTK $55.84
- Revenue Next Year
- POR $4.35
- CYTK $646.96
- P/E Ratio
- POR $14.83
- CYTK N/A
- Revenue Growth
- POR 10.79
- CYTK 412.21
- 52 Week Low
- POR $40.05
- CYTK $31.67
- 52 Week High
- POR $49.85
- CYTK $68.44
- Technical
- Relative Strength Index (RSI)
- POR 48.65
- CYTK 29.83
- Support Level
- POR $41.40
- CYTK $31.67
- Resistance Level
- POR $42.94
- CYTK $43.51
- Average True Range (ATR)
- POR 0.84
- CYTK 1.97
- MACD
- POR 0.07
- CYTK -0.78
- Stochastic Oscillator
- POR 54.31
- CYTK 0.21
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.